Corning Jerry KN046 combined with chemotherapy for the treatment of advanced pancreatic cancer phase III registration clinical trial application was approved by CDE

Suzhou, China, November 24, 2021/PRNewswire/ - Corning Jereh Biopharmaceuticals (stock code: 9966.

KN046-303 is a multi-center, randomized, double-blind, phase III clinical study conducted in patients with unresectable locally advanced or metastatic pancreatic cancer without systemic treatment.

Pancreatic cancer is one of the common malignant tumors of the digestive tract, with a high fatality rate.

Albumin paclitaxel combined with gemcitabine (AG regimen) is the standard first-line treatment regimen for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma, but the ORR of this regimen is less than 25%, and it is rapidly progressing, and there is a huge clinical demand

KN046 is a PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.

About KN046

KN046 is a PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.

KN046 has carried out nearly 20 clinical trials of different stages covering more than 10 types of tumors such as non-small cell lung cancer, thymic cancer, pancreatic cancer, liver cancer, esophageal squamous cell carcinoma, triple negative breast cancer, etc.

About Corning Jerry

Corning Jereh Biopharmaceuticals focuses on the research and development, production and commercialization of innovative anti-tumor drugs

Corning Jereh Biopharmaceuticals has a discovery, R&D, and manufacturing platform for the entire industry chain in bispecific antibody and protein engineering

The company has multiple technical platforms with independent intellectual property rights such as heterodimers and hybrid antibodies, and large-scale production capabilities that comply with China, the United States and the European Union cGMP standards, and have passed a complete quality system including multiple audits of the European Union QP.

Welcome to visit the company website: